The recently published article by Cepeda et al compiling pain trial data from the ClinicalTrials.gov database is important for the large number of randomized trials summarized (>7,000 trials).
1Much of the analysis focuses on attrition. However, several issues arising from the analyses warrant comment.
- Cepeda M.S.
- Lobanov V.
- Berlin J.A.
Use of ClinicalTrials.gov to estimate condition-specific nocebo effects and other factors affecting outcomes of analgesic trials.
J Pain. 2013; 14: 405-411
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to The Journal of Pain
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Use of ClinicalTrials.gov to estimate condition-specific nocebo effects and other factors affecting outcomes of analgesic trials.J Pain. 2013; 14: 405-411
- Enriched enrolment with randomized withdrawal (EERW): Time for a new look at clinical trial design in chronic pain.Pain. 2008; 135: 217-220
- Two-stage enriched enrolment pain trials: A brief review of designs and opportunities for broader application.Pain. 2010; 148: 8-13
- Placebo response in neuropathic pain trials.Pain. 2008; 138: 479-483
© 2013 American Pain Society. Published by Elsevier Inc. All rights reserved.